Market Research Report
Physician Perspectives 2017: Biosimilar use in IBD
|Published by||GlobalData||Product code||721700|
|Published||Content info||54 Pages
Delivery time: 1-2 business days
|Physician Perspectives 2017: Biosimilar use in IBD|
|Published: February 1, 2018||Content info: 54 Pages||
This Physician Perspectives survey focuses on the use of biosimilar anti-TNFs in IBD.
In the next 12 months, nearly half of physicians stated that they would consider switching Remicade patients (in remission) over to biosimilar IFX. A large proportion of physicians reported that their patients have at least occasionally expressed concern (rated >3) over being switched onto a biosimilar anti-TNF from an originator anti-TNF (67%) or being prescribed a biosimilar anti-TNF (54%). Overall, the majority of physicians agreed that they would require a biosimilar to be designated as interchangeable before considering switching patients from an originator to a biosimilar (67%).
The report includes following topics -